Intellectia Proprietary Trading Signals: No signal on given stock today. (No AI Stock Picker buy/sell day-trade edge; no recent SwingMax entry)
Buy now: price (~39.7 pre-market) is trading right on/just below key support (S1 ~39.94), with an oversold short-term RSI and strong Street price-target momentum.
Base case (impatient entry): favorable risk/reward for a near-term rebound back toward the pivot (42.20) and then resistance (44.46), supported by bullish options positioning and multiple post-earnings target raises.
Timing catalyst: next earnings (QDEC 2025) on 2026-02-19 (AH) can keep attention/positioning elevated into the print.
Politicians/congress: no recent congress trading data available; no noted influential-figure activity in provided data.
Technical Analysis
Trend/Momentum: MACD histogram -0.205 and negatively expanding → momentum is still bearish, suggesting the down-move hasn’t fully reversed yet.
Overextension: RSI_6 26.9 → short-term oversold conditions, which often supports a bounce attempt if support holds.
Moving averages: converging MAs → consolidation phase; next directional break likely comes from support/resistance levels.
Key levels:
Support: S1 39.94 (price is slightly below in pre-market), then S2 38.55.
Resistance: Pivot 42.20, then R1 44.46, R2 45.85.
Pattern-based forward odds (from similar candlesticks): ~+0.83% next week, +10.74% next month bias supports a buy-for-rebound stance despite weak immediate MACD.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning (Open Interest): Put/Call OI ratio 0.14 (calls dominate) → generally bullish/optimistic positioning.
Volume: Put/Call volume ratio 0.0 with 0 reported volume → today’s tape isn’t providing fresh sentiment confirmation.
Volatility: 30D IV ~60% vs historical vol ~24% → options are pricing elevated move risk; IV percentile ~61% (moderately high vs its own history).
Net Income: $6.495M, down sharply YoY (profitability volatility).
EPS: $0.13, down sharply YoY.
Growth read-through: top-line and gross margin trends are constructive, but the earnings line is currently less stable—supports a “buy for growth/rebound” case more than a “buy for pristine earnings consistency” case.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: broad, same-day wave of price target increases following Q3 results; the Street is leaning bullish.
Upgrades/raises (highlights):
Oppenheimer: PT $50 (from $40), Outperform.
Lake Street: PT $55 (from $45), Buy.
Stifel: PT $55 (from $46), Buy.
Citizens JMP: PT $53 (from $47), Outperform.
Canaccord: PT $51 (from $50), Buy.
Ladenburg: PT $40 (from $38), Neutral (notably the most cautious among recent notes).
Wall Street pros: beat-and-raise quarter, confidence in sustained double-digit revenue growth, and improving EBITDA/margin profile narrative.
Wall Street cons: at least one Neutral stance with a much lower PT ($40) implies less upside conviction at current levels; profitability variability remains a watch item.
Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is 51.71 USD with a low forecast of 40 USD and a high forecast of 58 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast AORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AORT is 51.71 USD with a low forecast of 40 USD and a high forecast of 58 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 39.460
Low
40
Averages
51.71
High
58
Current: 39.460
Low
40
Averages
51.71
High
58
Ladenburg
Jeffrey Cohen
Neutral
maintain
$38 -> $40
AI Analysis
2025-11-07
Reason
Ladenburg
Jeffrey Cohen
Price Target
$38 -> $40
AI Analysis
2025-11-07
maintain
Neutral
Reason
Ladenburg analyst Jeffrey Cohen raised the firm's price target on Artivion to $40 from $38 and keeps a Neutral rating on the shares.
Oppenheimer
Oppenheimer
Outperform
maintain
$40 -> $50
2025-11-07
Reason
Oppenheimer
Oppenheimer
Price Target
$40 -> $50
2025-11-07
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Artivion to $50 from $40 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 revenue of $113.4M, +16% year-over-year, above its/consensus estimate of $112M/$110M. FY25 revenue guidance was raised, now $439M-$445M, and management remains confident about double-digit top-line growth.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AORT
